BIOVENTIX PLC (BVXP)

BIOVENTIX PLC (BVXP)

Seminars

ShareSoc Growth Company Seminar, London, October 2018

Click here for the Volition Investor Presentation Click here for the Stockopedia Reports

ShareSoc Growth Company Seminar, London, April 2017

Click here for Stockopedia Reports Click here for the Report on the ShareSoc Seminar Presentations Click here for Cornhill Capital Presentation

ShareSoc Company Supper, Richmond, June 2016

Blog posts

Investing for Income – More Than Just Seeking a High Yield

Vanishing Dividends Every week brings news of a major company cutting or suspending its dividend: this week, it was BT. For investors who rely upon dividends for income, the search for a reliable, sustainable dividend becomes ever harder. There are no shortage of commentators who believe that most companies should be putting dividends on hold now. Certainly, the story of Easyjet paying out significant dividends on the same day as it requested a bail out from the government struck many as irresponsible. When ...

New Year Share Tips – Are They Worth Following?

It’s that time of year when financial magazines and newsletters analyse their past share tip performance and give their New Year tips. Are the tips worth picking up or...

Mello Event, ProVen and ShareSoc Seminars and Lots More News

It’s been a busy last two days for me with several events attended. The first was on Tuesday when I attended the Mello London event in Chiswick. It was...

AGM Reports

Bioventix (BVXP) AGM 2019

After the euphoria of a sweeping Conservative election victory, at least for stock market investors, it’s back to more humdrum business. Here’s a report on the Annual General Meeting of Bioventix (BVXP) which was held yesterday. Bioventix is developer of antibodies used in medical diagnostics. It’s a small company with only 12 employees but revenue was up 16% last year to £9.3 million and EPS up by 3.7%. Talking to CEO Peter Harrison before the meeting, he indicated there would be no problems ...

Bioventix Plc (BVXP) AGM Report 2015

Yesterday I attended the Annual General Meeting of Bioventix Plc at the Mercure Bush hotel, Farnham, Surrey. Bioventix is a small (market Cap is £64.5 million) company that specialises in the development and commercial supply of high-affinity monoclonal antibodies with a focus on their application in clinical diagnostics. Results for the year ended 30th June 2015 were as follows: Revenues up 23% to £4.3 million, profit up 39% to £3.1 million and cash balances up £780k to £4.13m. Much of this revenue ...

Bioventix (BVXP) AGM Report 2014

Bioventix (BVXP) is a small company that has recently listed on AIM. To quote from the company's web site: "Bioventix is a biotechnology company specialising in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The high-affinity antibodies created at Bioventix have advantages over conventional rodent monoclonal antibodies where the target is present at low concentration, or where the target is a hapten or small molecule. ...